An international team of researchers has used genetic engineering to create the first ever “product-ready” antivenom for ...

DENVER, Nov. 04, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market ...

Immunologist Zachary Rubin explains how the World Health Organization decides which strains of influenza end up in annual flu ...

CollPlant Biotechnologies , a regenerative and aesthetic medicine company developing innovative technologies and products ...

The collaboration between the University and CyanoCapture will focus on developing innovative methods for producing targeted delivery systems using engineered carboxysomes, combining advanced ...

The University of Liverpool rand CyanoCapture Ltd are joining forces to develop the next generation of carboxysome-based ...

Collplant Holdings ( ($CLGN) ) has issued an announcement. On October 27, 2025, CollPlant Biotechnologies announced the expansion of its ...

A head-to-head study by Israel's Technion found that CollPlant's rhCollagen-based bioink, Collink.3D™, outperformed Matrigel®, a leading extracellular ...

An update from Collplant Holdings ( ($CLGN) ) is now available. On October 16, 2025, CollPlant Biotechnologies announced the development of a ...

GEAC and RCGM remain robust, science-driven regulatory bodies committed to biosafety and public interest; constructive ...

NLS Pharmaceutics Ltd. ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and neurodegenerative disorders and Kadimastem Ltd. ("Kadimastem"), a clinical-stage ...

RESEARCHERS at Massachusetts Institute of Technology (MIT) have developed a method to purify gene therapies 10 times more quickly than conventional processes, paving the way to lower prices for the ...